Smart Patients Get Smart Care™

The World’s Leading Authority for Chronic Lymphocytic Leukemia Patients

March 26, 2015

In November, 2014, I attended a meeting in Thessaloniki, Greece organized by the European School of Hematology (ESH), ESH 2014: International Conference on New Concepts in B Cell Malignancies: From molecular pathogenesis to personalized treatment. This video interview discussing predictive and prognostic markers in chronic lymphocytic leukemia (CLL) is
Take Away Points: Cancer by its nature is genomic unstable. Over time it acquires more mutations. New clones and sub-clones can arise over time. Therapy can influence the balance and evolution of the clonal and sub-clonal populations. Preface: Hematology in general and CLL specifically are full of jargon and
Take Away Points: CLL evolves drastically over time, but the seeds of the population that leads to resistance and relapse may be present from the very start. There is more to the story than the cancer itself. CLL’s microenvironment and host immune system’s response also evolve. “There has never
While we are not primarily focused on the corporate landscape in CLL, it makes sense to stay abreast of the business news that might influence what drugs get to market and how fast, what combinations are explored in clinical trials, what’s it will eventually cost, how good is insurance